dm+d

Unassigned

New Medicines

Metastatic, hormone receptor-positive breast cancer - second- and subsequent-line

Information

New molecular entity
Syndax Pharmaceuticals
Syndax Pharmaceuticals

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Sep 20Development discontinued. Earlier in May 2020, Syndax announced that the E2112 trial did not achieve the primary endpoint of demonstrating a statistically significant OS benefit over hormone therapy alone. As a result the Company has decided to de-prioritise the entinostat program to focus resources on advancing the remainder of its pipeline [14].

Category

Small molecule inhibitor of class I histone deacetylases, key enzymes that alter the structure of chromatin to control gene expression
The incidence of BC in the UK is about 80 per 100,000 people. About 40% develop metastatic disease.
Metastatic, hormone receptor-positive breast cancer - second- and subsequent-line
Oral

Evidence based evaluations

Advanced non-small cell lung cancer (NSCLC)

Information

New molecular entity
Syndax Pharmaceuticals
Syndax Pharmaceuticals

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Sep 20Development discontinued. Earlier in May 2020, Syndax announced that the E2112 breast cancer trial did not achieve the primary endpoint of demonstrating a statistically significant OS benefit over hormone therapy alone. As a result the Company has decided to de-prioritise the entinostat program to focus resources on advancing the remainder of its pipeline [11].

Category

orally active histone deacetylase inhibitor (HDACi) derived from benzamide
UK incidence of advanced NSCLC is 40 per 100,000 people; 25% are able to have first-line therapy, of these 20-40% may receive second-line therapy.
Advanced non-small cell lung cancer (NSCLC)
Oral